Green Pharmaceuticals Thursday obtained approval from the Food and Drug Administration for a non -opioid pain medication, paving the way to the deployment of a product which simultaneously sparked great hopes and mixed opinions among doctors and market analysts.
The drug, Journavx, has been approved for the treatment twice a day of moderate to severe acute pain, such as the type of short but cutting -edge that could follow a bicycle accident or an operation. The FDA decision was based on a pair of advanced trials that found that patients undergoing kid or onion surgery had much less pain after taking the medication than those who took a placebo. These trials also noted that the drug was generally safe, with fewer unwanted events among those on Journavx than in the placebo group.
Journavx was at $ 31 per day. Market analysts have planned that the drug could bring in $ 1.5 billion in annual income by 2030. This does not include chronic pain sales, where there is a larger market opportunity and where the summit also organizes tests.
This article is exclusive to stat + subscribers
Unlock this article – plus daily coverage and analysis of the biotechnological sector – in SUT +subscription.
Do you already have an account? Connect
Show all plans
